Drug
Iparomlimab clinical trials
- studies test it
- 20
- open now
- 20
- in phase 3
- 0
- first study started
- 2023
Keep track of what changes. Save the iparomlimab studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Name
Combined with it in one product
Studies by the year they started
20 studies that test it; most in 2025 (10)
| Year | Studies |
|---|---|
| 2023 | 1 |
| 2025 | 10 |
| 2026 | 9 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 1
- Phase 2
- 18
- Phase 4
- 1
- No phase
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 0 · Other 20
Second Affiliated Hospital of Nanchang University (2) · Tianjin Medical University Cancer Institute and Hospital (2) · Hebei Medical University Fourth Hospital (2) · Fudan University (1) · Jiangsu Cancer Institute & Hospital (1) · Changhai Hospital (1) · Zheng Min (1) · The Second Affiliated Hospital of Dalian Medical University (1)
Often tested with
Tested in the same studies.
Tuvonralimab (18) · Paclitaxel (3) · Bevacizumab (2) · Carboplatin (2) · Cisplatin (2) · Albumin-Bound Paclitaxel (2) · Lenvatinib (1) · Sacituzumab tirumotecan (1)
Studies
Open first, then newest update. How each study uses iparomlimab is read from its arms, and is right about nine times in ten.
Testing it · 20
- Assessing Iparomlimab and Tuvonralimab in Recurrent or Metastatic MSI-H/dMMR Gastric CancerRecruitingPhase 2Peking UniversityNCT07127822Written as Iparomlimab and Tuvonralimab
- Radiotherapy + Systemic Therapy as Conversion Therapy for pMMR/MSS T4M0 Colon Cancer（Neo-Color）RecruitingPhase 2Hebei Medical University Fourth HospitalNCT06949111Written as Iparomlimab and Tuvonralimab Injection
- Iparomlimab and Tovorilimab (QL1706) Combined With Bevacizumab and Chemotherapy as Neoadjuvant Therapy for Advanced Ovarian CancerNot yet recruitingPhase 2Fudan UniversityNCT07663513Written as Iparomlimab and Tuvonralimab Injection + Bevacizumab + Paclitaxel + Carboplatin
- Iparomlimab and Tuvonralimab in HNSCCRecruitingPhase 2Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong UniversityNCT07090317Written as Iparomlimab and Tuvonralimab
- Chemoradiation Plus Iparomlimab Consolidation in Older With ESCCRecruitingPhase 2Tianjin Medical University Cancer Institute and HospitalNCT07038629Written as Iparomlimab
- Neoadjuvant QL1706 in Patients With Hormone Receptor Positive, HER2-negative Breast CancerRecruitingPhase 2RenJi HospitalNCT07396324Written as Iparomlimab and Tuvonralimab
- A Clinical Study of Iparomlimab and Tuvonralimab Combined With Bevacizumab and Alternating Triweekly CAPOX/mCAPIRI Regimen as First-line Treatment for Unresectable Advanced Colorectal CancerNot yet recruitingPhase 2Jiangsu Cancer Institute & HospitalNCT07446387Written as Iparomlimab and tuvonralimab
- Iparomlimab and Tuvonralimab Combined With SFRT and Definitive Chemoradiotherapy in Locoregionally Advanced Bulky HNSCCNot yet recruitingPhase 2Second Affiliated Hospital of Nanchang UniversityNCT07041788Written as Iparomlimab and Tuvonralimab Injection
- A Study Investigating the Efficacy and Safety of the Combination of Iparomlimab and Tuvonralimab With or Without Chemotherapy in Second-line and Subsequent Treatments for Recurrent or Metastatic Head and Neck Squamous Cell CarcinomaRecruitingNot applicableThe Second Affiliated Hospital of Hainan Medical UniversityNCT07546383Written as Iparomlimab and tuvonralimab
- A Prospective, Single-Arm, Exploratory Study of the Safety and Efficacy of Neoadjuvant Treatment With QL1706, an Anti-PD-1/Anti-CTLA-4 Bispecific Antibody, in Resectable Stage IB and IIA Hepatocellular Carcinoma With High Recurrence RiskNot yet recruitingPhase 2Tianjin Medical University Cancer Institute and HospitalNCT07515469Written as Iparomlimab and Tuvonralimab
- Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular TypingRecruitingPhase 2Peking Union Medical CollegeNCT06145308Written as iparomlimab + tuvonralimab
- Neoadjuvant Therapy With Iparomlimab and Tuvonralimab, Lenvatinib and Chemotherapy in Resectable ESCCNot yet recruitingPhase 2Changhai HospitalNCT07490002Written as Iparomlimab and Tuvonralimab+Lenvatinib + Cisplatin/Carboplatin + Nab-paclitaxel
- Iparomlimab and Tuvonralimab Combined With Nimotuzumab in Recurrent or Metastatic NPC After First-line Treatment Failure: A Single-arm Phase IIa Clinical TrialRecruitingPhase 2Sun Yat-sen UniversityNCT07101744Written as Iparomlimab and Tuvonralimab
- A Phase II Study of Neoadjuvant Sacituzumab Tirumotecan in Combination With Iparomlimab and Tuvonralimab in Locally Advanced Cervical CancerNot yet recruitingPhase 2Zheng MinNCT07348861Written as Sacituzumab tirumotecan plus Iparomlimab
- Iparomlimab and Tuvonralimab Injection Combined With Chemotherapy and Sequential Thoracic Radiotherapy for Extensive-Stage Small Cell Lung CancerNot yet recruitingPhase 2The Second Affiliated Hospital of Dalian Medical UniversityNCT07349225Written as Iparomlimab and Tuvonralimab Injection
- Iparomlimab and Tuvonralimab Plus Chemotherapy for Inducing Conversion to Resectability in Initially Unresectable Stage III NSCLCNot yet recruitingPhase 2Chang ChenNCT07139041Written as Iparomlimab and tuvonralimab plus chemotherapy
- Iparomlimab and Tuvonralimab Injection for Untreated Locally Advanced Nasopharyngeal CarcinomaNot yet recruitingPhase 2Second Affiliated Hospital of Nanchang UniversityNCT07135804Written as Iparomlimab and Tuvonralimab Injection
- Study of Iparomlimab and Tuvonralimab Plus Chemotherapy in Malignant MesotheliomaNot yet recruitingPhase 1/2National Cancer Center, ChinaNCT07131345Written as iparomlimab and tuvonralimab (Dual PD-1/CTLA-4 blockade) + chemotherapy
- Efficacy and Safety of Iparomlimab and Tuvonralimab Injection in Combination With Bevacizumab After Progression on Anti-PD-(L)1 Therapy in Advanced Melanoma: A Prospective, Single-Arm, Exploratory Clinical StudyNot yet recruitingPhase 4Hebei Medical University Fourth HospitalNCT07004335Written as Iparomlimab and Tuvonralimab Injection plus Bevacizumab
- Neoadjuvant QL1706 Therapy for ESCCRecruitingPhase 2Shandong Provincial HospitalNCT06908382Written as Iparomlimab and Tuvonralimab Injection
Given in every arm · 11 — iparomlimab is usual care beside what is tested
- SBRT Combined With Iparomlimab and Tuvonralimab (QL1706) and Bevacizumab for Hepatocellular CarcinomaNot yet recruitingPhase 2Peking University Cancer Hospital & InstituteNCT07882056Written as Iparomlimab and Tuvonralimab
- Cryoablation Combined With Hepatic Arterial Infusion of Iparomlimab and Tuvonralimab (QL1706), Intravenous Dacarbazine, and Oral Lenvatinib in Patients With Liver Metastases From Malignant Melanoma: a Single-arm, Phase II, Prospective TrialRecruitingPhase 2Sun Yat-sen UniversityNCT07847359Written as Iparomlimab and Tuvonralimab
- A Single-arm, Multicenter Clinical Study of Iparomlimab and Toripalimab in Combination With Bevacizumab and Chemotherapy as First-line Treatment for Advanced Biliary Tract CancerRecruitingPhase 4Xianglin YuanNCT07619235Written as Iparomlimab and Toripalimab
- Neoadjuvant Therapy of Iparomlimab and Tuvonralimab Combined With Lenvatinib for Hepatocellular CarcinomaRecruitingPhase 2Peking Union Medical College HospitalNCT07014150Written as Iparomlimab and Tuvonralimab
- Iparomlimab and Tuvonralimab Plus Hypofractionated Radiotherapy and Chemotherapy for HAHNSCCRecruitingPhase 2Second Affiliated Hospital, School of Medicine, Zhejiang UniversityNCT07447570Written as Iparomlimab and Tuvonralimab injection
- Safety and Efficacy of Fruquintinib Plus Nab-Paclitaxel and Iparomlimab and Tuvonralimab Injection in the Second-Line Treatment for Immunotherapy-experienced Advanced Gastric CancerRecruitingPhase 2Dai, GuanghaiNCT07392346Written as Iparomlimab and Tuvonralimab
- CAPOX and Bevacizumab With or Without Primary Tumor Radiotherapy and Iparomlimab and Tuvonralimab as First-line Treatment for RAS-Mutant/MSS Metastatic Rectal CancerNot yet recruitingPhase 2Peking University Cancer Hospital & InstituteNCT07383285Written as Iparomlimab and Tuvonralimab
- Safety and Efficacy of IB-FOLFIRI in BRAF V600E-Mutant Metastatic Colorectal CancerRecruitingPhase 2Sun Yat-sen UniversityNCT07150247Written as Iparomlimab and Tuvonralimab
- Neoadjuvant Radiotherapy Plus Tegafur, Oxaliplatin and Iparomlimab and Tuvonralimab in Resectable Gastric and GE-junction Cancer : A Randomized, Two-arm, Prospective Trial (TRIUNITE-05)RecruitingPhase 2Daping Hospital and the Research Institute of Surgery of the Third Military Medical UniversityNCT07165847Written as Iparomlimab and Tuvonralimab
- Radiotherapy Combined QL1706, TAS-102 and Bevacizumab in mCRCNot yet recruitingPhase 2Jinan Central HospitalNCT07116577Written as Iparomlimab and tuvonralimab
- Iparomlimab and Tuvonralimab With Chemoradiation for the Treatment of Locally Recurrent and Oligometastatic Cervical CancerRecruitingPhase 2Shandong Cancer Hospital and InstituteNCT06942416Written as Iparomlimab and Tuvonralimab
Codes
What other systems call iparomlimab · ClinicalTrials.gg INT016576
- UNII (FDA) FN3VWV28BCIPAROMLIMABOne source FDA
- NCI Thesaurus C184814IparomlimabOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | FN3VWV28BC | IPAROMLIMAB | One source FDA |
| NCI Thesaurus | C184814 | Iparomlimab | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.